A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes.

Bain, S; Feher, M; Fisher, M; Hex, N; Lee, K C S; Mahon, J; Russell-Jones, D; Schou, H; Wilmot, E G; Baxter, M

Bain, S; Feher, M; Fisher, M; Hex, N; Lee, K C S; Mahon, J; Russell-Jones, D; Schou, H; Wilmot, E G; Baxter, M.

Affiliation

Bain S; Diabetes Research Unit Cymru, University Medical School, Swansea, UK.
Feher M; Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
Fisher M; Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.
Hex N; York Health Economics Consortium Ltd, University of York, York, UK.
Lee KCS; Sanofi, Paris, France.
Mahon J; York Health Economics Consortium Ltd, University of York, York, UK.
Russell-Jones D; Department of Diabetes and Endocrinology, Royal Surrey County Hospital and University of Surrey, Guildford, UK.
Schou H; Sanofi, Guildford, UK.
Wilmot EG; Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS FT, Derby, UK.
Baxter M; Sanofi, Guildford, UK.

Diabet Med ; 37(2): 219-228, 2020 02.

Article de En | MEDLINE | ID: mdl-31729775

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Hémoglobine glyquée / Diabète de type 1 / Hypoglycémiants / Insuline Type d'étude: Guideline / Systematic_reviews Limites: Humans Langue: En Journal: Diabet Med Sujet du journal: ENDOCRINOLOGIA Année: 2020 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google